I guess your right about HIV. Here's the release:
LONDON--(BUSINESS WIRE)--Aug. 27, 1999--
Gateway Capital Begins Coverage of Cel-Sci Corporation (HIV) With a STRONG BUY Recommendation and a Price Target of $105 Per Share
Gateway Capital Partners Inc. announced today that it has initiated research coverage of CEL-SCI CORPORATION (AMEX: HIV-news) with a "STRONG BUY" recommendation and established a twelve month price target of $105.00 per share. HIV is a biopharmaceutical company developing potentially breakthrough products in the field of immunotherapy.
Highlights of the Report
MULTIKINE
-- Multikine (Leukocyte Interleukin Injection) is a patented immunotherapeutic agent, which consists of a mixture of naturally occurring cytokines including interleukins, interferons, chemokines and colony-stimulating factors.
-- Multikine activates and boosts the local immune response.
-- It has induced tumor reduction and tumor necrosis in phase
I/II trials of head and neck cancer.
-- Multikine has shown minimal side effects.
-- It may be effective against all solid tumors since it is
tumor nonspecific.
-- Enormous market potential
HGP-30W AIDS VACCINE
-- HGP-30W is a prophylactic vaccine designed to induce cellular and humoral immune responses against the predominant subtypes of HIV-1 worldwide, designed to prevent or reduce the severity of infection by HIV.
-- HGP-30W is based on a region of the AIDS virus that is less variable and less subject to mutation. HGP-30W produces killer T-cells to destroy the virus-infected cells
-- In animal and human studies, HGP-30W has been shown to generate immune responses that potentially recognize the major HIV subtypes, representing more than 90% of the world's AIDS cases.
-- It is inherently safe, since a synthetic peptide cannot cause infection, such as vaccines using infectious, attenuated or killed viruses
-- Phase II study currently ongoing in Europe
-- Patent protected
L.E.A.P.S
- L.E.A.P.S. (Ligand Epitope Antigen Presentation System) induces
the body's immune system in a way most likely to eliminate or
control disease.
- L.E.A.P.S. is a modulation technology platform that may allow
development of new immunotherapies and/or vaccines for infectious
diseases, cancer, autoimmune diseases, allergic asthma and
allergies.
- Any disease for which antigenic epitope sequences have been
identified, such as bacterial, viral, parasitic infections,
cancer, autoimmune diseases, allergic asthma and allergy, are
good candidates for this technology.
- HIV, Herpes simplex, malaria, tuberculosis, prostate and breast
cancer therapies under development provide enormous market
potential.
- Patent protected.
Gateway Capital believes a premium valuation of $105 per share is well justified for Cel-Sci Corporation. "This company has potential products with extraordinary financial potential and may be the future premier biopharmaceutical company."
Gateway Capital Partners Inc. provides investment research worldwide.
All material herein was prepared by Gateway Capital Partners Inc. (GCP) based upon information and sources believed to be reliable. The information contained herein is not guaranteed by GCP to be accurate, and should not be considered to be all-inclusive. This discussion contains forward-looking statements that involve risks and uncertainties. A company's actual results could differ materially from those described in any forward-looking statements or announcements discussed within. The material is for information purposes only. Please consult a broker before purchasing or selling any securities mentioned in this report. GCP has not been compensated for the preparation and distribution of this report and has issued the report on an unsolicited basis. GCP, its affiliates, and/or its officers, directors and employees may buy, sell or have a position in the securities discussed in this report.
CONTACT:
Gateway Capital Partners Inc., Norfolk (England)
44 1553 691 631
BW1012 AUG 27,1999
2:57 PACIFIC
5:57 EASTERN
|
